Represented in over 100 countries, our commercial sales have strong coverage across North America (34%), Europe (41%), and the rest of world (>25%) with our medicines showing best-in-class commercial performance.

Our North America base has grown rapidly: 600% over the last 6 years reaching >$1bn in 2022.

Since 2020, Ipsen has brought in over 20 best- or first-in-class programs across our pipeline at every stage of development and plans are in place to acquire more.

We are focused. We invest in opportunities in challenging disease areas to better address challenges faced by the community.

Ipsen acquired Epizyme in 2022, and with it Tazverik^® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor, strengthening our oncology pipeline and reinforcing our focus on solid tumors and hematological malignancies.

In 2023, Ipsen acquired Albireo, accelerating our growth in rare disease with treatments for pediatric liver diseases. With Bylvay^® (odevixibat), we boost our expertise in treating pruritus in young people with progressive familial intrahepatic cholestasis (PFIC). In addition, Bylvay^® is in registration for Alagille syndrome and in Phase III trials for biliary atresia. This partnership also results in a number of other assets joining our clinical pipeline.

Ipsen was named 2022 Pharma BD Team of the Year at the European Lifestars Awards.

Guided by our strategy, we move fast to make deals with like-minded partners. That’s how we were able to make two acquisitions in less than nine months.